We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Viatris (VTRS) Q1 Earnings Preview: What You Should Know Beyond the Headline Estimates
Read MoreHide Full Article
Wall Street analysts forecast that Viatris (VTRS - Free Report) will report quarterly earnings of $0.68 per share in its upcoming release, pointing to a year-over-year decline of 12.8%. It is anticipated that revenues will amount to $3.74 billion, exhibiting an increase of 0.4% compared to the year-ago quarter.
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
That said, let's delve into the average estimates of some Viatris metrics that Wall Street analysts commonly model and monitor.
The combined assessment of analysts suggests that 'Net Sales- Developed Markets' will likely reach $2.26 billion. The estimate points to a change of +4.1% from the year-ago quarter.
Analysts predict that the 'Net Sales- Greater China' will reach $518.24 million. The estimate points to a change of -8.2% from the year-ago quarter.
The consensus among analysts is that 'Net Sales- JANZ' will reach $312.47 million. The estimate points to a change of -8.7% from the year-ago quarter.
Analysts expect 'Net Sales- Emerging Markets' to come in at $643.13 million. The estimate suggests a change of +0.2% year over year.
According to the collective judgment of analysts, 'Net Sales- Developed Markets- Brands' should come in at $1.28 billion. The estimate suggests a change of +4.1% year over year.
Based on the collective assessment of analysts, 'Other revenues' should arrive at $10.00 million. The estimate indicates a change of 0% from the prior-year quarter.
It is projected by analysts that the 'Net Sales- JANZ- Brands' will reach $167.30 million. The estimate points to a change of -51.1% from the year-ago quarter.
The consensus estimate for 'Net Sales- JANZ- Generics' stands at $145.17 million. The estimate points to a change of -0.4% from the year-ago quarter.
Analysts' assessment points toward 'Net Sales- Emerging Markets- Brands' reaching $420.93 million. The estimate points to a change of -3.4% from the year-ago quarter.
Analysts forecast 'Net Sales- Emerging Markets- Generics' to reach $222.20 million. The estimate points to a change of +7.8% from the year-ago quarter.
The collective assessment of analysts points to an estimated 'Total Net Sales' of $3.73 billion. The estimate indicates a year-over-year change of +0.4%.
The average prediction of analysts places 'Net Sales- Developed Markets- Generics' at $976.11 million. The estimate indicates a year-over-year change of +20.7%.
Viatris shares have witnessed a change of -0.2% in the past month, in contrast to the Zacks S&P 500 composite's -1.6% move. With a Zacks Rank #3 (Hold), VTRS is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Viatris (VTRS) Q1 Earnings Preview: What You Should Know Beyond the Headline Estimates
Wall Street analysts forecast that Viatris (VTRS - Free Report) will report quarterly earnings of $0.68 per share in its upcoming release, pointing to a year-over-year decline of 12.8%. It is anticipated that revenues will amount to $3.74 billion, exhibiting an increase of 0.4% compared to the year-ago quarter.
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
That said, let's delve into the average estimates of some Viatris metrics that Wall Street analysts commonly model and monitor.
The combined assessment of analysts suggests that 'Net Sales- Developed Markets' will likely reach $2.26 billion. The estimate points to a change of +4.1% from the year-ago quarter.
Analysts predict that the 'Net Sales- Greater China' will reach $518.24 million. The estimate points to a change of -8.2% from the year-ago quarter.
The consensus among analysts is that 'Net Sales- JANZ' will reach $312.47 million. The estimate points to a change of -8.7% from the year-ago quarter.
Analysts expect 'Net Sales- Emerging Markets' to come in at $643.13 million. The estimate suggests a change of +0.2% year over year.
According to the collective judgment of analysts, 'Net Sales- Developed Markets- Brands' should come in at $1.28 billion. The estimate suggests a change of +4.1% year over year.
Based on the collective assessment of analysts, 'Other revenues' should arrive at $10.00 million. The estimate indicates a change of 0% from the prior-year quarter.
It is projected by analysts that the 'Net Sales- JANZ- Brands' will reach $167.30 million. The estimate points to a change of -51.1% from the year-ago quarter.
The consensus estimate for 'Net Sales- JANZ- Generics' stands at $145.17 million. The estimate points to a change of -0.4% from the year-ago quarter.
Analysts' assessment points toward 'Net Sales- Emerging Markets- Brands' reaching $420.93 million. The estimate points to a change of -3.4% from the year-ago quarter.
Analysts forecast 'Net Sales- Emerging Markets- Generics' to reach $222.20 million. The estimate points to a change of +7.8% from the year-ago quarter.
The collective assessment of analysts points to an estimated 'Total Net Sales' of $3.73 billion. The estimate indicates a year-over-year change of +0.4%.
The average prediction of analysts places 'Net Sales- Developed Markets- Generics' at $976.11 million. The estimate indicates a year-over-year change of +20.7%.
View all Key Company Metrics for Viatris here>>>
Viatris shares have witnessed a change of -0.2% in the past month, in contrast to the Zacks S&P 500 composite's -1.6% move. With a Zacks Rank #3 (Hold), VTRS is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>